Bispecific Antibody Development Service
Service Overview
JWE specializes in the development of high-quality targeted therapeutic antibodies, particularly nanobodies (VHH) and bispecific antibodies (bsAbs). Bispecific antibodies are single antibody molecules capable of binding two different antigens simultaneously, enabling combined target intervention. They demonstrate superior clinical efficacy and safety, especially in tumor immunotherapy and antiviral applications, and represent a frontier research focus.
Mechanism of Action Categories
- Cell-bridging type: Bridges target cells with effector cells
- Dual-target blocking type: Simultaneously blocks signaling from two targets
- Immune-cell activation type: Activates effector immune cell functions
- Same-cell-surface protein bridging type: Regulates intracellular signaling within the same target cell
Structural Categories
Structurally, bispecific antibodies can be divided into full-length IgG-like and fragment-based formats. Structural design is crucial for functionality. JWE’s platform supports design and optimization of diverse bispecific architectures, including:
- KIH (Knob-into-Hole)
- CrossMab
- DVD-I
- IgG-VHH fusion format: Combines IgG stability with VHH small-size specificity, a signature format of our platform
Recombinant Expression Service
JWE operates a mature mammalian cell recombinant expression platform, supporting serum-free suspension culture in 293F and CHO cells to ensure high-quality expression of bispecific antibodies in their native conformations. The workflow follows GMP-like control, including cell seed testing, source documentation, animal-component quality control, and standardized SOPs.
Service Workflow and Timeline
| Step | Service Content | Deliverables | Timeline |
|---|---|---|---|
| Step 1 |
Bispecific antibody design and construction - Parent antibody affinity validation - Confirmation of bispecific structure design - Linker optimization |
Raw sequencing data, validation data, experimental report | 4–5 weeks |
| Step 2 |
In vitro functional validation - Plasmid transient expression + purification + SDS-PAGE/WB analysis - EC50/FACS binding and blocking assays |
Experimental data, materials, experimental report | 6–10 weeks |
| Step 3 |
Stable expression (optional) - CHO stable cell line generation and screening - Fermentation product purification |
Stable cell line, construction report, product samples | 12–14 weeks |
Platform Advantages
- Mature platform: extensive experience with high success rate in bispecific design
- Diverse bispecific formats: supports IgG-VHH, full-length IgG, fragment-based structures
- High-quality recombinant expression: strict QC ensures native conformation and function
- Fully customized service: design tailored to client needs for precise R&D
